Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.65 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13039739 | 0.99 | HDAC1 (0.73) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL13039733 | 0.97 | HDAC1 (0.70) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL13039740 | 0.90 | HDAC6 (0.70) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL13039732 | 0.89 | HDAC6 (0.68) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL1521148 | 0.83 | HDAC8 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL1232986 | 0.79 | HDAC1 (0.79) | HDAC1HDAC8HDAC6HDAC3HDAC2 | |
| SCHEMBL2225891 | 0.79 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL1938212 | 0.79 | HDAC3 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL25676227 | 0.79 | HDAC3 (0.59) | HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL13039735 | 0.78 | HDAC6 (1.00) | HDAC1HDAC8HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278782-A1 | DIFFERENTIATION OF RAT LIVER EPITHELIAL CELLS INTO HEPATOCYTE-LIKE CELLS | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100196929-A1 | STABILISATION OF THE PHENOTYPIC PROPERTIES OF ISOLATED PRIMARY CELLS | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278782-A1 | DIFFERENTIATION OF RAT LIVER EPITHELIAL CELLS INTO HEPATOCYTE-LIKE CELLS | MYADM, GLS2, HNF4A | HDAC1 4216/4885HDAC8 3692/4885HDAC6 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.